AXSM
Axsome Therapeutics Inc
179.30$
-1.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 11.3% | 10.3% | 8.4% | 9.2% | 8.1% | 8.9% | 8.1% | 9.0% | 7.0% | 6.3% | 7.7% | 6.2% | 6.8% | |
| 88.7% | 89.7% | 91.6% | 90.8% | 91.9% | 91.1% | 91.9% | 91.0% | 93.0% | 93.7% | 92.3% | 93.8% | 93.2% | |
| 49.8% | 43.1% | 49.1% | 57.2% | 43.3% | 46.3% | 36.9% | 33.0% | 23.5% | 24.9% | 27.6% | 21.2% | 24.2% | |
| 95.3% | 87.7% | 100.0% | 84.0% | 91.2% | 73.3% | 99.4% | 62.8% | 63.6% | 86.4% | 96.8% | 95.3% | 86.4% | |
| 196.2% | 227.1% | 181.3% | 180.3% | 151.7% | 152.3% | 138.9% | 115.5% | 120.0% | 108.7% | 125.4% | 116.5% | 117.5% | |
| -107.5% | -137.4% | -89.7% | -89.5% | -59.8% | -61.1% | -46.9% | -24.5% | -27.0% | -15.0% | -33.1% | -22.7% | -24.3% | |
| 1.3% | 1.0% | 1.4% | 1.5% | 1.9% | 1.9% | 2.0% | 1.2% | 0.7% | 0.6% | 0.6% | 0.7% | 0.6% | |
| -108.8% | -138.4% | -91.1% | -91.0% | -61.7% | -63.0% | -48.9% | -32.6% | -27.6% | -14.4% | -33.8% | -23.4% | -24.6% | |
| -1.2% | -0.5% | 0.0% | – | – | 0.1% | – | -0.6% | – | 0.2% | – | 0.1% | – | |
| -107.6% | -137.9% | -91.1% | -91.0% | -61.7% | -63.1% | -48.9% | -32.0% | -27.6% | -14.6% | -33.8% | -23.5% | -24.7% | |
| -104.5% | -135.0% | -87.3% | -87.3% | -57.8% | -59.4% | -45.2% | -28.4% | -26.0% | -12.6% | -31.9% | -22.7% | -23.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.